Speciality Medicines Ltd Share Price – BSE

Pharmaceuticals, Small Cap

The domestic equity benchmarks remained under pressure in mid-afternoon trade with sharp losses as investor sentiment stayed cautious due to uncertainty over the reopening of the Strait of Hormuz and crude oil prices rising above $100 per barrel. Investors are also closely monitoring Q4 earnings for further cues. The Nifty traded below 24,250 mark.

PSU Bank shares witnessed profit booking after rallying in the previous four trading sessions.

At 14:25 IST, the barometer index, the S&P BSE Sensex declined 717.65 points or 0.92% to 77,780.63. The Nifty 50 index slumped 160.50 points or 0.68% to 24,210.15.

In the broader market, the BSE 150 MidCap Index shed 0.25% and the BSE 250 SmallCap Index fell 0.33%.

The market breadth was negative. On the BSE, 1,754 shares rose and 2,441 shares fell. A total of 192 shares were unchanged.

The NSE's India VIX, a gauge of the market's expectation of volatility over the near term, rose 0.99% to 18.48.

Economy:

The HSBC Flash India PMI Composite Output Index was rose to 58.3 in April from the final reading of 57.0 in March. The latest reading signalled a sharp expansion in overall business activity, remaining well above its long-run average.

HSBC Flash India Services PMI Business Activity Index stood at 57.9 in April 2026 compared with 57.5 in March 2026.

Meanwhile, HSBC Flash India Manufacturing PMI Output Index climbed to 59.1 im April 2026 compared with 55.7 in March 2026. Overall manufacturing business conditions also strengthened, with the HSBC Flash India Manufacturing PMI rising to 55.9 in April from 53.9 in the previous month.

The foreign broker has downgraded Indian equities to ?underweight? from ?neutral.? The move comes amid rising crude oil prices driven by the Middle East conflict. Brent crude is up over 40% and trading above $100 per barrel. Higher oil prices are expected to raise inflation and slow growth. It said earnings forecasts may be revised lower. A 20% rise in crude could cut earnings growth by 1.5%.

The brokerage also flagged risks of rupee depreciation and continued foreign investor outflows. Concerns around IT sector demand remain. While domestic inflows are supportive, valuations may look expensive if earnings are downgraded. The brokerage said selective opportunities remain, but the broader outlook has weakened.

Buzzing Index:

The Nifty PSU Bank index declined 2.25% to 25,927.35. The index increased 2.55% in the past four consecutive trading sessions.

Union Bank of India (down 7.8%), Bank of Maharashtra (down 2.75%), Canara Bank (down 2.66%), Indian Bank (down 1.98%), Bank of Baroda (down 1.92%), Punjab National Bank (down 1.7%), Central Bank of India (down 1.68%), Bank of India (down 1.52%), Punjab & Sind Bank (down 1.49%) and State Bank of India (down 1.1%) declined.

Numbers to Track:

The yield on India's 10-year benchmark federal paper rose 0.32% to 6.945 compared with previous session close of 6.923.

In the foreign exchange market, the rupee edged lower against the dollar. The partially convertible rupee was hovering at 94.1125 compared with its close of 93.7850 during the previous trading session.

MCX Gold futures for 5 June 2026 settlement declined 0.38% to Rs 152,073.

The US Dollar Index (DXY), which tracks the greenback's value against a basket of currencies, was up 0.08% to 98.67.

The United States 10-year bond yield advanced 0.58% to 4.319.

In the commodities market, Brent crude for June 2026 settlement jumped $1.87 or 1.83% to $103.78 a barrel.

Stocks in Spotlight:

Speciality Medicines hit an upper limit of 5% after the company announced a new export order from an international client.

Jio Financial Services rallied 4.61% after the company said that it has entered into a binding agreement with Allianz Group (Allianz) to form a 50:50 primary insurance joint venture (JV).

Speciality Medicines has finalized a commercial arrangement with an international entity that specializes in importing and distributing the pharmaceutical finished products, supporting its future growth. Under the said deal, the said entity has agreed to distribute, market and sell the products of the company of value of USD 2 million (an approximate value of Rs 18.8 crore).

The company said it has entered into a commercial arrangement with a global distributor for pharmaceutical finished products worth about $2 million, or approximately Rs 18.8 crore.

Under the agreement, the overseas partner will distribute, market and sell the company?s products, expanding its international reach.

The company said the deal is expected to strengthen its distribution network and improve revenue visibility going forward.

It added that the transaction is not a related party deal and none of the promoters have any interest in the arrangement.

Speciality Medicines is engaged in the marketing, distribution and contract manufacturing of specialty pharmaceutical formulations used in areas such as oncology, immunology, neurology and rare diseases. Its portfolio includes high-value oral and injectable therapies across multiple dosage forms.

For the period ended 31 October 2025, the company reported revenue from operations of Rs 36.72 crore and net profit of Rs 6.06 crore.

The company was listed on the BSE SME platform on 30 March 2026 at Rs 124, in line with its IPO price. The issue was subscribed 2.19 times.

The scrip was listed at Rs 124, matching the initial public offer (IPO) price. The counter hit a high of Rs 129.50 and a low of Rs 124. About 13.38 lakh shares of the company changed hands at the counter.

Speciality Medicines' IPO was subscribed 2.19 times. The issue opened for bidding on 20 March 2026 and it closed on 24 March 2026. The price band of the IPO was fixed between Rs 117 to Rs 124 per share.

The IPO comprised fresh issue of 23,50,000 equity shares. The company intends to utilise the net proceeds for setting up a research and development (R&D) centre in Valsad, Gujarat; product registration in international markets; product development for sale in international markets; funding marketing and promotional activities; meeting working capital requirements and for general corporate purposes.

Speciality Medicines is involved in the marketing, distribution, and contract manufacturing of specialty pharmaceutical formulations used to treat complex and chronic conditions across areas such as oncology, immunology, neurology, and rare diseases. The company offers a broad portfolio of high-cost oral and injectable therapies in multiple dosage forms, including tablets, injections, inhalers, and infusions. Its operations are structured around two integrated models: contract manufacturing of approved formulations for international markets and the sourcing, marketing, and distribution of specialty pharmaceutical products from other manufacturers. As of 28 February 2026, the company had a total of 18 permanent employees across various departments.

The company recorded revenue from operations of Rs 36.72 crore and net profit of Rs 6.06 crore for the period ended 31 October 2025.

Powered by Capital Market - Live News